Methotrexate Accord Healthcare Ireland (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This inhibition disrupts DNA, RNA, and protein synthesis, particularly in rapidly dividing cells such as immune cells and cancer cells, thereby reducing inflammation and tumor proliferation.

The dose of methotrexate is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. Dosage regimens can vary widely, so the prescriber determines the appropriate amount and schedule for each patient.

Methotrexate is classified as contraindicated in pregnancy because it can cause fetal malformations and miscarriage. It is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Methotrexate is often considered a first‑line DMARD because of its proven efficacy, oral availability, and relatively low cost compared with biologic agents. While biologics target specific cytokines, methotrexate works at the cellular level to suppress immune activity, making it a versatile option for many patients.

Methotrexate Accord Healthcare Ireland should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Maintaining these conditions helps preserve tablet integrity and potency throughout its shelf life.

The product is supplied as oral tablets and is taken by mouth with or without food, as directed by the prescriber. Some treatment protocols may start with a low dose and gradually increase, while others may use a weekly dosing schedule depending on the indication.

Serious risks include severe liver toxicity, bone‑marrow suppression leading to anemia or infection, and pulmonary fibrosis. Patients should be monitored regularly for liver enzymes, complete blood counts, and respiratory symptoms to detect these complications early.

Methotrexate is contraindicated in patients with known hypersensitivity to the drug, severe renal or hepatic impairment, active infections, and in pregnant or nursing women. It should also be avoided in individuals receiving live vaccines or those with uncontrolled immune disorders without specialist supervision.